– USA, CA – Artiva Biotherapeutics, Inc., an oncology company today announced the appointment of Dr. Laura Bessen (M.D.) to its Board as an independent director, bringing decades of global pharmaceutical industry experience in medical leadership roles spanning clinical development, medical affairs, and product launches.
About Dr. Laura Bessen
Dr. Bessen was most recently VP, Head of US Medical from 2012 to 2016 at Bristol Myers Squibb, where she was responsible for all US Medical Affairs, including phase IV clinical trials Dr. Bessen retired in 2016 from Bristol Myers Squibb after 15 years in leadership positions, most recently as VP, Head of US Medical. Previously at BMS, she was VP, Head of US Medical Immunoscience and Neuroscience; and before that, Head of Immunoscience and Oncology Global Medical Affairs. Before BMS, Dr. Bessen was at DuPont Pharmaceuticals in medical affairs leadership roles. She currently provides strategic and board-level advice as managing partner of Maxsam Advisors LLC.
Dr. Bessen received her M.D. degree from New York University School of Medicine and B.S. in biochemistry from the State University of New York at Binghamton. She trained in internal medicine at Mount Sinai Medical Center, NY, and infectious diseases at Albert Einstein College of Medicine.
About Artiva Biotherapeutics
Artiva’s mission is to deliver highly effective, off-the-shelf, allogeneic natural killer cell-based therapies, utilizing our Manufacturing-First approach, that are safe and accessible to cancer patients. Artiva’s pipeline includes AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. The company is currently advancing a Phase 1/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas. Artiva’s pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and AB-202, a CD19-specific CAR-NK cell therapy candidate for the treatment of B-cell malignancies. The company has entered into therapeutic NK cell collaborations with Merck Sharp & Dohme Corp. and with Affimed GmbH. Artiva’s AlloNK platform incorporates cell expansion, activation, and engineering technology developed by the Company’s strategic partner, GC Cell Corporation, a member of the GC family of companies, a leading healthcare company in Korea. Artiva is headquartered in San Diego.
For more information: https://www.artivabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.